Letters

Safety of tamoxifen

BMJ 1994; 308 doi: https://doi.org/10.1136/bmj.308.6941.1438a (Published 28 May 1994) Cite this as: BMJ 1994;308:1438
  1. V C Jordan
  1. Robert H Lurie Cancer Centre, Northwestern University Medical School, Chicago, Illinois, USA.

    EDITOR, - Rivalry among pharmaceutical companies and their products is a fact of modern life. But Gary M Williams overstates concerns about tamoxifen, and, in suggesting that toremifene, an antioestrogen that is not yet approved for treating advanced breast cancer in Britain or the United States, should be substituted for tamoxifen in prevention studies, he is suggesting the use of a drug whose long term toxicological effects in women are unknown.1 The rationale for his recommendation is that large doses of tamoxifen cause liver tumours in rats but toremifene does not.2 Had I found that tamoxifen was producing liver tumours in rats two decades ago I would not have advocated long term adjuvant tamoxifen treatment for node …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe